Exalpha Biologicals, Inc.

Product Highlight

FIX&PERM Cell Fixation and Permeabilization Kit

Flow cytometric analyses with monoclonal antibodies were so far mainly restricted to cell surface molecules. Intracellular structures such as cytoplasmic or nuclear enzymes, oncoproteins, cytokines, immunoglobulins etc. were largely excluded from such studies. Also excluded from flow cytometric studies were cytoplasmic localizations of well-established membrane molecules like CD3 and CD22, which, in their cytoplasmic form, are the most reliable lineage markers in undifferentiated leukemia. With the FIX&PERM® Kit flow cytometric analysis of intracellular antigens has become as easy as surface antigen studies. The only prerequisite is the availability of suitable antibody conjugates. Most of the available monoclonal antibody conjugates can be used with the FIX&PERM® Kit, some determinants are sensitive, however, to the fixation step involved. This and the optimal fixation time have to be tested for each reagent.

News

Welcome, Peter Rutten

We are pleased to announce that Peter Rutten has now started in his role as Operations Director here at Exalpha Biologicals Inc. Peter has a Master’s of Science degree in Industrial and Organizational Psychology and this has lead him down a very business orientated career path. Peter is looking forward to working with the team at Exalpha. Peters primary focus is the customer experience and he will be working with the Laboratory team, the Quality Control team and the Order Processing team to ensure this focus is achieved. We all wish Peter well in his new role.

Exalpha Biologicals, Inc.

Cytochrome p450 26A1

  • Product Code: X2049M
  • Size: 200 µg
  • Availability: In Stock In Stock
  • Price (USD): $232

Cat #

X2049M		 Quantity:      

Data Sheet

Product Name

Cytochrome p450 26A1

Synonyms

CYP450 26 (EC 1.14.-.-); Retinoic acid-metabolizing cytochrome; P450 retinoic acid-inactivating 1; P450RAI; hP450RAI; Retinoic acid 4-hydroxylase

Host/Source

Mouse

Clone

F27 P6 A1

Isotype

IgG1

Product Type

Monoclonal Antibody

Reactivity

Human

Applications

ELISA, Western Blot, Immunohistochemistry

Purification

Protein A/G Chromatography

Size

200 µg

Price (USD)

$232

Background

The cytochrome P450 proteins (CYPs) are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP26A1, also referred to as retinoic acid-4-hydroxylase, is a major retinoic acid catabolic enzyme. CYP26A1 plays an important role in protecting tailbud tissues from inappropriate exposure to retinoic acid. CYP26A1 transcription is epigenetically regulated by nuclear retinoic acid receptors 2. Mutations in the gene encoding for CYP26A1 are associated with caudal agenesis and spina bifida, imperforate anus, agenesis of the caudal portions of the digestive and urogenital tracts, and malformed lumbosacral skeletal elements. CYP26A1 is upregulated in adenomatous polyposis coli mouse adenomas, human FAP adenomas, human sporadic colon carcinomas, and in the intestine of adenomatous polyposis coli(mcr) mutant zebrafish embryos.

Immunogen

Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with a synthetic peptide derived from the C-terminus of the human CYP450 26A1 protein and mouse myeloma Ag8563 cells.

Positive Control

Liposarcoma cells

Formulation

Provided as solution in phosphate buffered saline with 0.08% sodium azide

Customer Storage

Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles

Target Molecular Weight

49 kDa

Product Image

Image Legend

A. Immunohistochemical staining of liposarcoma cells using CYP26A1 antibody (cat. no. X2049M). B. Western blot on recombinant protein corresponding to C-terminal region of CYP26A1 protein using CYP26A1 antibody.

Database Links:

SwissProtO43174Human

References

1. Kumarakasingham, M., et al. (2005). Cytochrome p450 profile of colorectal cancer: Identification of markers of prognosis. Clin. Cancer Res. 11(10);3758-3765.

2. Sakai, Y., et al. (2004). CYP26A1 and CYP26C1 cooperate in degrading retinoic acid within the equatorial retina during later eye development. 276(1);143-157

3. Osanai, M. and Petkovich, M. (2005). Expression of the retinoic acid-metabolizing enzyme CYP26A1 limits programmed cell death. 67(5);1808-1817